Cyclotek has signed an agreement with Johns Hopkins University, for the exclusive Australian and New Zealand rights to the PSMA PET tracer DCFPyL. This novel tracer is labelled with Fluorine-18, and can be readily distributed from centralised manufacturing sites just like FDG. Cyclotek operates four cyclotron facilities, with a capacity to supply imaging sites throughout Australia and New Zealand. DCFPyL will be manufactured under GMP, alongside a number of other PET tracers for oncology and neurodegenerative diseases, which are currently available from Cyclotek.
[contact-form-7 id=”714″ title=”Update Form”]